VKORC1 (Q9BQB6) variants and mutations
VKORC1 (also known as Q9BQB6) is a human protein-coding gene encoding a vitamin K epoxide reductase complex subunit 1 protein. It recycles vitamin K to support gamma-carboxylation of coagulation proteins and is the direct pharmacologic target of warfarin. Common variants strongly influence warfarin dose requirements, while rare variants can cause warfarin resistance or vitamin-K-dependent clotting-factor deficiency. This analysis covers 395 VKORC1 variants and mutations. Of these, 85% have computational variant effect predictions. Disease context includes Hereditary combined deficiency of vitamin K-dependent clotting factors, vitamin K-dependent clotting factors, combined deficiency of, type 2, and atrial fibrillation. Example VKORC1 variants include M1I, G2D, and G2S.
Variant analysis overview
- Gene: VKORC1
- Protein: Q9BQB6
- UniProt accession: Q9BQB6
- Organism: Homo sapiens
- Variants analyzed: 395
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 210 unspecified-consequence records; 3 stop lost; 1 stop retained variant; 127 missense variants; 11 frameshift variants; 7 stop-gained variants; 25 synonymous variants; 2 in-frame deletions; 1 in-frame insertions; 1 splice-region variants; 6 substitution
- Prediction scores: 336 variants have prediction scores (85% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Hereditary combined deficiency of vitamin K-dependent clotting factors, vitamin K-dependent clotting factors, combined deficiency of, type 2, atrial fibrillation, thrombotic disease, pulmonary embolism, Recurrent thrombophlebitis, myocardial infarction, stroke disorder, Venous thrombosis, venous thromboembolism, Thromboembolism, neurodegenerative disease.
Protein structure and variant hotspots
- Protein features: 4 transmembrane segments; 4 binding sites.
- Structural context: 216 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable VKORC1 variants
Examples include M1I, G2D, G2S, S3R, T4A, T4N, T4S, W5*. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs886042699, ClinGen CA10604581, ClinVar RCV000281566, MetaLR 0.83, MetaSVM 0.60, Uncertain significance, not provided
- G2D (p.Gly2Asp), ExAC rs757332613, gnomAD rs757332613, REVEL 0.55, CADD 22.90
- G2S (p.Gly2Ser), gnomAD rs1352037555
- S3R (p.Ser3Arg), gnomAD rs1464695762, REVEL 0.24, CADD 17.00
- T4A (p.Thr4Ala), ExAC rs749237507, TOPMed rs749237507, gnomAD rs749237507, REVEL 0.28, CADD 16.30
- T4N (p.Thr4Asn), ExAC rs756150795, gnomAD rs756150795, REVEL 0.32, CADD 17.70
- T4S (p.Thr4Ser), ExAC rs756150795, gnomAD rs756150795, REVEL 0.24, CADD 16.40
- W5* (p.Trp5Ter), ExAC rs752892359, TOPMed rs752892359, gnomAD rs752892359, CADD 36.00
- W5C (p.Trp5Cys), TOPMed rs1008191003, gnomAD rs1008191003, REVEL 0.57, CADD 24.00
- W5L (p.Trp5Leu), ExAC rs752892359, TOPMed rs752892359, gnomAD rs752892359, REVEL 0.59, CADD 24.30
- W5S (p.Trp5Ser), rs752892359, ClinGen CA395733154, ClinVar RCV004482561, REVEL 0.68, CADD 24.40, Uncertain significance, not specified
- G6E (p.Gly6Glu), gnomAD rs1159008015
- G6R (p.Gly6Arg), gnomAD rs2057317246, REVEL 0.22, CADD 7.36
- S7I (p.Ser7Ile), ExAC rs755166588, TOPMed rs755166588, gnomAD rs755166588, REVEL 0.22, CADD 10.80
- S7N (p.Ser7Asn), ExAC rs755166588, TOPMed rs755166588, gnomAD rs755166588, REVEL 0.25, CADD 7.74
- P8L (p.Pro8Leu), gnomAD rs1482710449, REVEL 0.69, CADD 27.10
- P8S (p.Pro8Ser), 1000Genomes rs200328478, ExAC rs200328478, gnomAD rs200328478, REVEL 0.68, CADD 25.80
- G9D (p.Gly9Asp), gnomAD rs1028424472, CADD 0.52
- W10* (p.Trp10Ter), ExAC rs763425395, TOPMed rs763425395, gnomAD rs763425395, CADD 34.00
- W10C (p.Trp10Cys), ExAC rs763425395, TOPMed rs763425395, gnomAD rs763425395, REVEL 0.61, CADD 24.10
- W10L (p.Trp10Leu), ExAC rs766721996, gnomAD rs766721996, REVEL 0.39, CADD 22.50
- W10S (p.Trp10Ser), ExAC rs766721996, gnomAD rs766721996, REVEL 0.61, CADD 22.80
- V11L (p.Val11Leu), 1000Genomes rs547713296, TOPMed rs547713296, gnomAD rs547713296, REVEL 0.35, CADD 15.20
- V11M (p.Val11Met), 1000Genomes rs547713296, TOPMed rs547713296, gnomAD rs547713296, REVEL 0.51, CADD 17.10
- R12P (p.Arg12Pro), gnomAD rs1291155948, REVEL 0.88, CADD 25.70
- R12Q (p.Arg12Gln), gnomAD rs1291155948
- R12W (p.Arg12Trp), TOPMed rs1238672542, REVEL 0.91, CADD 27.30
- R12C (p.Arg12Cys), rs763546199, []
- A14G (p.Ala14Gly), gnomAD rs1303702908, REVEL 0.51, CADD 22.30
- A14P (p.Ala14Pro), TOPMed rs993371943, gnomAD rs993371943, REVEL 0.77, CADD 22.90, Uncertain significance
- A14T (p.Ala14Thr), rs993371943, ClinGen CA280622560, ClinVar RCV004361448, TOPMed rs993371943, REVEL 0.59, CADD 21.00, Uncertain significance, not specified
- L15V (p.Leu15Val), Ensembl rs2057316510, REVEL 0.57, CADD 22.20
- C16R (p.Cys16Arg), ExAC rs763546199, gnomAD rs763546199
- C16S (p.Cys16Ser), TOPMed rs1386462679, gnomAD rs1386462679, REVEL 0.84, CADD 24.70
- L17Q (p.Leu17Gln), gnomAD rs1158566246, REVEL 0.68, CADD 23.90
- T18M (p.Thr18Met), gnomAD rs1458185698, REVEL 0.32, CADD 14.80
- G19S (p.Gly19Ser), gnomAD rs1163079898, REVEL 0.77, CADD 24.20
- V21L (p.Val21Leu), Ensembl rs2057316166, REVEL 0.23, CADD 12.40
- L22F (p.Leu22Phe), rs759258204, ClinGen CA8021308, ClinVar RCV003426679, ExAC rs759258204, REVEL 0.70, CADD 23.30, Uncertain significance, not provided
- L22V (p.Leu22Val), ExAC rs759258204, gnomAD rs759258204, REVEL 0.58, CADD 19.60, Uncertain significance
- S23* (p.Ser23Ter), cosmic curated COSV56232, TOPMed rs1414049720, gnomAD rs1414049720, CADD 36.00
- S23L (p.Ser23Leu), cosmic curated COSV10643, TOPMed rs1414049720, gnomAD rs1414049720
- S23W (p.Ser23Trp), TOPMed rs1414049720, gnomAD rs1414049720, REVEL 0.83, CADD 27.60
- Y25C (p.Tyr25Cys), gnomAD rs1484691721, REVEL 0.90, CADD 29.20
- Y25N (p.Tyr25Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A26E (p.Ala26Glu), ExAC rs749184875, gnomAD rs749184875, REVEL 0.85, CADD 27.50
- A26P (p.Ala26Pro), ExAC rs770703948, gnomAD rs770703948, REVEL 0.92, CADD 25.70
- A26S (p.Ala26Ser), ExAC rs770703948, gnomAD rs770703948, REVEL 0.53, CADD 21.70
- A26T (p.Ala26Thr), rs770703948, UniProt VAR 065785, ExAC rs770703948, gnomAD rs770703948, REVEL 0.86, CADD 23.60, Pathogenic, in CMRES
- L27M (p.Leu27Met), 1000Genomes rs549914326, ExAC rs549914326, TOPMed rs549914326, gnomAD rs549914326
- L27V (p.Leu27Val), 1000Genomes rs549914326, ExAC rs549914326, TOPMed rs549914326, gnomAD rs549914326, REVEL 0.78, CADD 24.60
- H28P (p.His28Pro), ExAC rs748308822, REVEL 0.91, CADD 28.10
- H28Q (p.His28Gln), ExAC rs755256488, TOPMed rs755256488, gnomAD rs755256488, REVEL 0.78, CADD 23.90
- V29G (p.Val29Gly), TOPMed rs1354359469, gnomAD rs1354359469, REVEL 0.93, CADD 29.80
- V29L (p.Val29Leu), rs104894539, ClinGen CA115412, ClinVar RCV000002291, UniProt VAR 021821, REVEL 0.87, CADD 25.80, Pathogenic, Warfarin response
- K30R (p.Lys30Arg), ExAC rs780403529, gnomAD rs780403529, REVEL 0.71, CADD 28.30
- A32E (p.Ala32Glu), TOPMed rs111897490, gnomAD rs111897490, CADD 7.11
- A32T (p.Ala32Thr), gnomAD rs1319950423, REVEL 0.43, CADD 23.60
- A32V (p.Ala32Val), TOPMed rs111897490, gnomAD rs111897490, CADD 7.57
- R33H (p.Arg33His), gnomAD rs1391461576, REVEL 0.42, CADD 21.70
- A34P (p.Ala34Pro), TOPMed rs887072982, gnomAD rs887072982, REVEL 0.68, CADD 26.80
- A34S (p.Ala34Ser), TOPMed rs887072982, gnomAD rs887072982, REVEL 0.49, CADD 23.90
- A34T (p.Ala34Thr), cosmic curated COSV56231, TOPMed rs887072982, gnomAD rs887072982, REVEL 0.50, CADD 24.00
- A34V (p.Ala34Val), TOPMed rs1273794953, gnomAD rs1273794953, REVEL 0.64, CADD 26.60
- R35G (p.Arg35Gly), ExAC rs762195886, TOPMed rs762195886, gnomAD rs762195886, REVEL 0.83, CADD 25.30
- R35Q (p.Arg35Gln), TOPMed rs1024627160, gnomAD rs1024627160, REVEL 0.64, CADD 26.00
- R35W (p.Arg35Trp), ExAC rs762195886, TOPMed rs762195886, gnomAD rs762195886, REVEL 0.81, CADD 32.00
- D36G (p.Asp36Gly), UniProt VAR 065786, Pathogenic, in CMRES
- D36N (p.Asp36Asn), 1000Genomes rs61742245, ESP rs61742245, ExAC rs61742245, TOPMed rs61742245, REVEL 0.33, CADD 21.10, Pathogenic, in CMRES
- D36Y (p.Asp36Tyr), rs61742245, ClinGen CA115418, ClinVar RCV000002296, ClinVar RCV001115529, REVEL 0.65, CADD 24.90, drug response, warfarin response - Dosage
- D36D (p.Asp36Asp), rs767124757, []
- R37P (p.Arg37Pro), Ensembl rs2057315310, REVEL 0.25, CADD 7.42
- R37W (p.Arg37Trp), rs1389217886, gnomAD rs1389217886, REVEL 0.31, CADD 22.80, Variant assessed as somatic; moderate impact.
- D38H (p.Asp38His), rs774078258, ClinGen CA8021292, ClinVar RCV004482560, ExAC rs774078258, REVEL 0.53, CADD 20.60, Uncertain significance, not specified
- D38Y (p.Asp38Tyr), ExAC rs774078258, TOPMed rs774078258, gnomAD rs774078258, REVEL 0.47, CADD 22.20, Uncertain significance
- Y39H (p.Tyr39His), gnomAD rs2057315224, REVEL 0.88, CADD 32.00
- L42F (p.Leu42Phe), ExAC rs770660797, gnomAD rs770660797, REVEL 0.56, CADD 23.40
- D44E (p.Asp44Glu), gnomAD rs1205034556, REVEL 0.89, CADD 25.10
- D44N (p.Asp44Asn), Ensembl rs1041421946, REVEL 0.69, CADD 31.00
- V45A (p.Val45Ala), rs104894540, ClinGen CA115413, ClinVar RCV000002292, UniProt VAR 021822, REVEL 0.88, CADD 24.60, Pathogenic, Warfarin response
- V45L (p.Val45Leu), NCI-TCGA TCGA novel, REVEL 0.44, CADD 21.30, Variant assessed as somatic; moderate impact., in CMRES
- V45M (p.Val45Met), TOPMed rs1198062672, REVEL 0.67, CADD 26.70
- G46D (p.Gly46Asp), TOPMed rs2057314958, REVEL 0.76, CADD 25.80
- T47I (p.Thr47Ile), ExAC rs772860822, TOPMed rs772860822, gnomAD rs772860822, REVEL 0.54, CADD 22.40
- T47T (p.Thr47Thr), rs2057304456, gnomAD 16-31093461-T-A, CADD 10.10
- T47S (p.Thr47Ser), gnomAD 16-31093471-G-C, CADD 6.25
- T47N (p.Thr47Asn), gnomAD 16-31093471-G-T, CADD 6.12
- A48S (p.Ala48Ser), gnomAD rs1229209080
- I49F (p.Ile49Phe), Ensembl rs2057314859
- I49M (p.Ile49Met), TOPMed rs2057314842, REVEL 0.80, CADD 24.00, Uncertain significance, not specified
- S50G (p.Ser50Gly), TOPMed rs2057314818
- C51Y (p.Cys51Tyr), TOPMed rs1479031158
- S52* (p.Ser52Ter), ExAC rs769806539, TOPMed rs769806539, CADD 41.00
- S52W (p.Ser52Trp), UniProt VAR 065788, Pathogenic, in CMRES
- R53C (p.Arg53Cys), ExAC rs781304132, TOPMed rs781304132, gnomAD rs781304132, REVEL 0.81, CADD 33.00
- R53H (p.Arg53His), TOPMed rs1423114055
- R53S (p.Arg53Ser), ExAC rs781304132, TOPMed rs781304132, gnomAD rs781304132, REVEL 0.78, CADD 26.20
- V54I (p.Val54Ile), gnomAD rs1299287925, REVEL 0.70, CADD 26.30
- V54A (p.Val54Ala), rs745410819, gnomAD 16-31093480-A-G, CADD 7.28
- F55L (p.Phe55Leu), rs1392107723, gnomAD rs1392107723, REVEL 0.81, CADD 24.20, Variant assessed as somatic; moderate impact.
- S56F (p.Ser56Phe), UniProt VAR 065789, REVEL 0.87, CADD 31.00, Pathogenic, in CMRES
- S57=, NCI-TCGA Cosmic COSV5623, Variant assessed as somatic; low impact.
- R58G (p.Arg58Gly), rs104894541, ClinGen CA115414, ClinVar RCV000002293, UniProt VAR 021823, AlphaMissense 0.17, MetaLR 0.92, Pathogenic, Warfarin response
- R58S (p.Arg58Ser), gnomAD 16-31093421-C-G, REVEL 0.80, CADD 26.20
- R58R (p.Arg58Arg), rs1250004939, gnomAD 16-31093482-C-T, CADD 8.60
- W59C (p.Trp59Cys), UniProt VAR 065790, Pathogenic, in CMRES
- W59L (p.Trp59Leu), UniProt VAR 065791, Pathogenic, in CMRES
- W59S (p.Trp59Ser), gnomAD 16-31093450-C-G, CADD 15.30
- R61K (p.Arg61Lys), rs2544126628, ClinGen CA395731079, ClinVar RCV004482562, REVEL 0.36, CADD 4.90, Uncertain significance, not specified
- R61S (p.Arg61Ser), NCI-TCGA TCGA novel, TOPMed rs1303260087, gnomAD rs1303260087, REVEL 0.52, CADD 14.60, Variant assessed as somatic; moderate impact.
- R61R (p.Arg61Arg), rs2057312367, gnomAD 16-31094277-C-T, CADD 7.86
- R61T (p.Arg61Thr), gnomAD 16-31094278-C-G, CADD 5.51
- R61M (p.Arg61Met), gnomAD 16-31094278-C-A, CADD 5.33
- G62A (p.Gly62Ala), Ensembl rs200917074
- G62S (p.Gly62Ser), gnomAD rs1158890375, REVEL 0.77, CADD 26.00
- G62V (p.Gly62Val), Ensembl rs200917074, REVEL 0.87, CADD 25.70
- F63L (p.Phe63Leu), gnomAD 16-31093406-G-C, REVEL 0.75, CADD 23.30
- G64E (p.Gly64Glu), gnomAD rs1410644433
- G64W (p.Gly64Trp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L65P (p.Leu65Pro), rs780768824, gnomAD 16-31093456-A-AG, CADD 17.70
- L65F (p.Leu65Phe), gnomAD 16-31093464-C-A, CADD 9.33
- L65V (p.Leu65Val), gnomAD 16-31093466-A-C, CADD 7.96
- V66G (p.Val66Gly), UniProt VAR 065792, CADD 13.20, Pathogenic, in CMRES
- V66M (p.Val66Met), rs72547529, ClinGen CA8021197, ClinVar RCV000853288, ClinVar RCV001120431, REVEL 0.62, CADD 25.40, Conflicting interpretations, Vitamin K-dependent clotting factors, combined deficiency of, type 2; Warfarin r
- V66L (p.Val66Leu), gnomAD 16-31093399-C-G, REVEL 0.57, CADD 23.10
- V66I (p.Val66Ile), rs778391072, gnomAD 16-31093460-C-T, CADD 4.20
- E67D (p.Glu67Asp), gnomAD 16-31093394-C-G, REVEL 0.62, CADD 19.90
- E67K (p.Glu67Lys), gnomAD 16-31093396-C-T, REVEL 0.65, CADD 24.30
- E67E (p.Glu67Glu), rs2057312279, gnomAD 16-31094265-C-T, CADD 7.45
- H68P (p.His68Pro), 1000Genomes rs201044348, ESP rs201044348, ExAC rs201044348, TOPMed rs201044348, Benign
- H68R (p.His68Arg), rs201044348, ClinGen CA8021194, cosmic curated COSV54927, ClinVar RCV001120429, REVEL 0.33, CADD 12.50, Benign, Vitamin K-dependent clotting factors, combined deficiency of, type 2
- H68Y (p.His68Tyr), rs145273772, ClinGen CA8021196, ClinVar RCV001120430, ESP rs145273772, REVEL 0.34, CADD 15.30, Uncertain significance, Vitamin K-dependent clotting factors, combined deficiency of, type 2
- H68Q (p.His68Gln), rs755827554, gnomAD 16-31093443-G-T, CADD 4.09
- H68H (p.His68His), rs755827554, gnomAD 16-31093443-G-A, CADD 4.66
- V69L (p.Val69Leu), TOPMed rs2057303711
- V69V (p.Val69Val), rs1034176818, gnomAD 16-31094268-T-C, CADD 9.99
- L70Q (p.Leu70Gln), gnomAD rs1209106306
- L70V (p.Leu70Val), 1000Genomes rs202194968, TOPMed rs202194968, gnomAD rs202194968, REVEL 0.63, CADD 22.50
- L70P (p.Leu70Pro), gnomAD 16-31093386-A-G, REVEL 0.86, CADD 28.20
- G71A (p.Gly71Ala), UniProt VAR 065794, Pathogenic, in CMRES
- G71G (p.Gly71Gly), gnomAD 16-31094280-G-T, CADD 0.51
- G71R (p.Gly71Arg), rs778247610, gnomAD 16-31094285-C-G, CADD 9.15
- Q72* (p.Gln72Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q72H (p.Gln72His), ExAC rs777358300, gnomAD rs777358300, REVEL 0.42, CADD 1.54
- Q72K (p.Gln72Lys), gnomAD rs570612024, REVEL 0.33, CADD 5.84
- Q72P (p.Gln72Pro), TOPMed rs2057303627
- Q72L (p.Gln72Leu), gnomAD 16-31093380-T-A, REVEL 0.39, CADD 5.56
- Q72E (p.Gln72Glu), gnomAD 16-31093381-G-C, REVEL 0.23, CADD 8.07
- D73H (p.Asp73His), gnomAD rs1226775184
- D73E (p.Asp73Glu), gnomAD 16-31092863-A-C, CADD 7.82
- D73A (p.Asp73Ala), gnomAD 16-31092864-T-G, CADD 3.98
- D73V (p.Asp73Val), gnomAD 16-31092864-T-A, CADD 6.79
- D73G (p.Asp73Gly), rs371197517, gnomAD 16-31092864-T-C, CADD 3.40
- D73T (p.Asp73Thr), gnomAD 16-31093377-TC-T, CADD 26.70
- D73Y (p.Asp73Tyr), gnomAD 16-31093378-C-A, REVEL 0.83, CADD 25.40
- S74N (p.Ser74Asn), gnomAD rs1378784538, REVEL 0.46, CADD 19.50
- S74G (p.Ser74Gly), gnomAD 16-31093375-T-C, REVEL 0.71, CADD 24.10
- I75L (p.Ile75Leu), NCI-TCGA Cosmic COSV5492, cosmic curated COSV54926, Variant assessed as somatic; moderate impact.
- L76P (p.Leu76Pro), gnomAD 16-31093368-A-G, REVEL 0.88, CADD 31.00
- L76F (p.Leu76Phe), gnomAD 16-31093369-G-A, REVEL 0.46, CADD 21.40
- L76H (p.Leu76His), rs1567421604, gnomAD 16-31093429-A-AGG, CADD 5.98
- N77S (p.Asn77Ser), rs2057303532, UniProt VAR 065795, TOPMed rs2057303532, gnomAD rs2057303532, REVEL 0.75, CADD 26.40, Uncertain significance, Vitamin K-dependent clotting factors, combined deficiency of, type 2
- N77Y (p.Asn77Tyr), rs755767348, UniProt VAR 065796, ExAC rs755767348, TOPMed rs755767348, REVEL 0.87, CADD 31.00, Likely pathogenic, not provided
- N77K (p.Asn77Lys), gnomAD 16-31093364-A-T, REVEL 0.80, CADD 24.90
- N77H (p.Asn77His), gnomAD 16-31093366-T-G, REVEL 0.81, CADD 27.70
- S79T (p.Ser79Thr), TOPMed rs1186082539
- S81T (p.Ser81Thr), gnomAD 16-31093353-C-G, REVEL 0.70, CADD 26.70
- S81R (p.Ser81Arg), gnomAD 16-31093354-T-G, REVEL 0.86, CADD 29.30
- I82T (p.Ile82Thr), gnomAD rs1454769993, REVEL 0.72, CADD 24.80
- I82V (p.Ile82Val), ExAC rs781032482, TOPMed rs781032482, gnomAD rs781032482, REVEL 0.28, CADD 15.20
- I82I (p.Ile82Ile), rs779628631, gnomAD 16-31094262-A-T, CADD 6.10
- F83C (p.Phe83Cys), Ensembl rs1057109736, REVEL 0.82, CADD 26.70
- F83L (p.Phe83Leu), NCI-TCGA Cosmic COSV9976, cosmic curated COSV99762, ExAC rs754924004, TOPMed rs754924004, REVEL 0.59, CADD 15.00, Variant assessed as somatic; moderate impact.
- F83V (p.Phe83Val), rs770312170, gnomAD 16-31093409-A-C, CADD 14.10
- G84C (p.Gly84Cys), ExAC rs751483513, TOPMed rs751483513, gnomAD rs751483513
- G84S (p.Gly84Ser), ExAC rs751483513, TOPMed rs751483513, gnomAD rs751483513, REVEL 0.82, CADD 28.00
- G84G (p.Gly84Gly), rs2057303312, gnomAD 16-31093343-A-G, CADD 7.55
- G84V (p.Gly84Val), gnomAD 16-31093344-C-A, REVEL 0.81, CADD 26.80
- G84R (p.Gly84Arg), gnomAD 16-31093345-C-G, REVEL 0.82, CADD 24.40
- G84* (p.Gly84Ter), gnomAD 16-31093397-C-A, CADD 13.90
Public VKORC1 analysis runs
- VKORC1 analysis run — VKORC1 (395 variants) — completed 2026-08-10